Go Pro
OTCMKTS:BAYRY

Bayer Aktiengesellschaft Q1 2025 Earnings Report

Bayer Aktiengesellschaft logo
$14.04 -0.24 (-1.65%)
As of 04:00 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.65
Consensus EPS
$0.63
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$15.27 billion
Expected Revenue
$13.39 billion
Beat/Miss
Beat by +$1.87 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Deutsche Bank Reaffirms Their Buy Rating on Bayer (0P6S)
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics. Consumer Health offers nonprescription products, including brands in pain relief, allergy care, dermatology, nutritional supplements and digestive health. Crop Science supplies seeds, crop-protection products and digital tools designed to support farmers and improve agricultural productivity.

Bayer has expanded its operations internationally through internal research and development, partnerships and acquisitions, including the acquisition of Monsanto in 2018, which strengthened its seeds and agricultural technology business. Bill Anderson has served as Bayer’s chief executive officer since June 2023 and also leads the company’s ongoing organizational transformation.

View Bayer Aktiengesellschaft Profile